Search
Mitumomab
go.drugbank.com/drugs/DB06462ExperimentalMitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.
IR502
go.drugbank.com/drugs/DB06463ExperimentalIR502 (Zorcell) is a potential treatment for psoriasis.
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Propentofylline
go.drugbank.com/drugs/DB06479ExperimentalCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigationalPrucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG, RESOLOR ® TABLETAS RECUBIERTAS DE 1 MGRopidoxuridine
go.drugbank.com/drugs/DB06485InvestigationalRopidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Synonyms: 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE, 2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO-Categories: Heterocyclic Compounds, 1-RingAplaviroc
go.drugbank.com/drugs/DB06497InvestigationalA spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.
Categories: Heterocyclic Compounds, 1-RingL523S
go.drugbank.com/drugs/DB06498Investigational[A175909] It has been investigated as a lung cancer vaccine. … According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S)